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The widespread recognition that obstructive sleep apnoea (OSA) represents an important risk factor for
motor vehicle accidents (MVA), which is reversed by successful therapy with continuous positive airway
pressure (CPAP), has led to a revision of annex III of the European Union (EU) directive on driving
licences that is subject to mandatory implementation by all member states from December 31, 2015 [1].
This directive was the result of recommendations from a working group established by the Transport and
Mobility Directorate of the European Commission in 2012 [2]. The directive states [1]:
• Applicants or drivers in whom a moderate or severe obstructive sleep apnoea syndrome is suspected
shall be referred for further authorised medical advice before a driving licence is issued or renewed.
They may be advised not to drive until confirmation of the diagnosis.
• Driving licences may be issued to applicants or drivers with moderate or severe obstructive sleep
apnoea syndrome who show adequate control of their condition and compliance with appropriate
treatment and improvement of sleepiness, if any, confirmed by authorised medical opinion.
• Applicants or drivers with moderate or severe obstructive sleep apnoea syndrome under treatment
shall be subject to a periodic medical review, at intervals not exceeding three years for drivers of group
1 [noncommercial drivers] and one year for drivers of group 2 [commercial drivers], with a view to
establish the level of compliance with the treatment, the need for continuing the treatment and
continued good vigilance.
While the recognition of OSA and its potential consequences on driving represents a major step towards
increased safety on the road, European pulmonologists and sleep specialists face several problems. First,
practical application of the directive is demanded from governments of member states. Since rules for
medical assessment before obtaining a driving licence differ among European states [3], a standardised
approach to implementation of the EU directive would be highly desirable. Second, patients with
diagnosed OSA represent the tip of the iceberg of a large population with unrecognised and untreated
sleep disordered breathing, and the new requirements established by the EU directive could considerably
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increase the number of requests for specialist evaluation, and lengthen waiting lists. Affordable medical
evaluations, and an acceptable timeframe to obtain the new or renewed driving licence, appear reasonable
targets, but screening for OSA on a large scale will put considerable strain on health systems throughout
Europe. Third, episodes of sleepiness at the wheel in the previous 2 years were reported by 17% of
European drivers in a recent survey, underlining that it is quite a common problem [4]. Sleepiness at the
wheel was associated with poor sleep, younger age, male sex, driving exposure, daytime sleepiness and a
high risk of OSA [4].
Although OSA increases the risk of traffic accidents [5], the disorder is associated with excessive daytime
sleepiness (EDS) in only ∼50% of patients. While reports differ, the majority of evidence supports the view
that driving risk in OSA is more closely related to the degree of daytime sleepiness than the objective
severity of sleep disordered breathing as measured by the frequency of apnoeas and hypopnoeas per hour
of sleep (apnoea–hypopnoea index) [6]. However, other factors can contribute to sleepiness in patients
with OSA, which include inadequate sleep time, time of day (early morning and afternoon), shift work,
sedative medications, poor sleep hygiene, other sleep disorders, and alcohol intake [7]. These additional
factors may be particularly important in commercial drivers. Furthermore, these factors, which are not
directly related to OSA severity, may contribute to some of the variability in reported sleepiness in patients
with differing levels of disease severity based on apnoea–hypopnoea index, and of course may also be
present in patients without OSA, thus contributing to accident risk. Effective OSA treatment, usually with
CPAP, rapidly resolves both apnoea and EDS in the large majority of affected patients [8, 9].
A possible way to deal with the problem of driving in OSA patients was proposed by the British Thoracic
Society (BTS) in 2014 [10]. The BTS statement on driving licence regulation pragmatically focused on the
evaluation and treatment of sleepy patients only [10]. However, UK subjects requesting a driving licence
receive detailed information about OSA symptoms, and have to report symptoms of sleepiness to their
general practitioner (GP). Moreover, the Driver and Vehicle Licensing Agency directly manages the
assessment, together with the GP or a specialist, if necessary [10]. Such a model is hardly applicable in
most EU member states, where the GP or specialist has to issue a medical certificate.
Subjective EDS in OSA patients is usually assessed by questionnaires, which are subjective and thus
susceptible to reporting bias by a driver who seeks to underestimate severity, whereas objective evaluation
is expensive, time consuming, and not well suited to being performed on a large scale. It is likely that the
EU directive will foster research to develop new tools to assess fitness to drive. Such tools are currently
lacking, and this is a major problem to face in the near future.
This lack of tools is particularly evident in the context of the assessment of sleepiness. The need for
practical guidelines for clinicians is particularly evident in a recent report demonstrating a lack of consensus
in clinicians’ judgement of fitness to drive in both untreated and CPAPtreated patients with OSA [11].
Because of the major impact the directive might have on sleep and pulmonary specialists, the European
Respiratory Society (ERS) and the European Sleep Research Society (ESRS) will jointly appoint a group of
experts to develop practical recommendations to cope with the problems raised by the new EU directive
on issuing driving licences in Europe. The European Lung Foundation (ELF) will also be involved,
providing the important point of view of patients with OSA. Patient involvement is particularly important
in order to minimise the risk of encouraging OSA patients to avoid seeking medical attention and
treatment because of the understandable concern that such a diagnosis would compromise their ability to
continue driving. This risk is particularly concerning for commercial drivers who depend on retention of a
valid driving licence for their livelihood and also represent the group where failure to diagnose and treat
OSA carries the greatest risk to public safety. In this context, a “carrot and stick” approach is required with
the principal emphasis being on the carrot, and a detailed campaign to educate patients, employers and
other relevant stakeholders about this topic is required.
Questions to be addressed by the group include the following. How should the suspicion of moderate or
severe OSA be justified? Are there simple and readily available tools to assess OSA and sleepiness in the
population? What is the consensus on a minimal medical expert standard to establish good compliance to,
and effectiveness of, treatment? Which tests or investigations should be used to certify continued good
vigilance? In addition to this document, planned for early 2016, further initiatives will be set up to obtain
additional information over time, and update/adjust recommendations.
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